INTRODUCTION
In the 1989 New England Journal of Medicine editorial "Resistance to Antiviral Drugs: the End of Innocence," Martin Hirsch and Robert Schooley highlighted the importance and ramifications of progressive herpetic disease resulting from drug-resistant herpesviruses in AIDS patients (64) . The emergence of herpes simplex viruses (HSV) resistant to antiviral drugs was not a new observation, for selection for resistance has generally not been difficult in cell culture (29) . Indeed, resistant HSV had also been recovered from patients (26, 42, 104, 105 ), but these viruses were not associated with, nor did they cause, progressive disease in the immunocompetent patient (7) . However, the emergence of drug-resistant herpesviruses in the immunosuppressed patient did result in progressive disease, as described in the articles accompanying the editorial (15, 46, 47) , as well as elsewhere (90) . In the intervening years since the Hirsch and Schooley editorial, greater attention has been paid to rapid detection of drug-resistant clinical isolates and the clinical importance of infections associated with drug-refractory herpesviruses in immunosuppressed patients. Indeed, the frequency of encountering acyclovir (ACV)-resistant HSV and ganciclovir (GCV)-resistant human cytomegalovirus (HCMV) has been increasing as the population of AIDS patients has mushroomed. As a result, increasing attention is being focused on defining the mechanisms involved in antiviral drug activities and resistance and on developing antiviral drugs with novel modes of action. The resistance problem has also heightened interest in evaluating the effi-2 FIELD AND BIRON GCV, and adenine arabinoside (ara-A), prodrugs that require phosphorylation to the respective triphosphates that are the active inhibitors of viral DNA polymerase (DNA pol), with resultant inhibition of viral DNA synthesis. In the second category are direct HSV DNA pol (HSV pol) inhibitors such as phosphonoformate (PFA; foscarnet) and phosphonoacetate. However, for primary and recurrent HSV, only ara-A (vidarabine), ACV (Zovirax), and PFA (Foscovir) are approved therapeutics in the United States.
ACV has by far gained the widest acceptance for clinical use. ACV is approved for topical application as an ointment for initial herpes genitalis and for limited non-life-threatening mucocutaneous herpes in immunocompromised patients; for oral administration in the treatment of primary and recurrent genital herpes and for herpes zoster; and for intravenous administration for mucosal and cutaneous HSV and herpes zoster infections in immunocompromised patients, as well as for HSV central nervous system infections (110) . The mechanism of antiviral activity of ACV involves two viral enzymes: one for activation of the drug, and the second as the target for inhibition of virus replication. In infected cells, ACV is selectively converted to ACV triphosphate (ACVTP), the viral DNA pol inhibitor, by phosphorylation to the 5'-monophosphate (ACVMP), using HSV-encoded deoxypyrimidine (thymidine) kinase (TK+ virus). ACVMP is then progressively converted to the 5'-di-and -triphosphates by cellular kinases. Finally, ACVTP inhibits viral DNA synthesis by acting as an HSV pol substrate analog which is incorporated into the nascent viral DNA chain. The resultant complex of viral polymerase and ACV-altered nascent DNA results in removal of functional HSV pol from further catalytic activity (113) . Since the antiviral activity of ACV is dependent on two viral functions, the TK and the HSV pol, resistance may result from either of two mechanisms: failure to phosphorylate ACV to the ACVMP or failure of ACVTP to inhibit HSV pol.
Resistance Due to Altered or Deficient HSV TK Resistance due to failure to phosphorylate ACV usually is the result of HSV mutants that express little or no functional TK (TK-). For instance, Palu et al. recently described a series of HSV-2 isolates obtained from an AIDS patient who had received extensive ACV treatment (103a) . The isolates were resistant to ACV because of a deficiency in TK production, the consequence of a chain-terminating mutation resulting in synthesis of a truncated TK polypeptide. Alternatively, TK-altered mutants in which the enzyme is capable of phosphorylating thymidine, the usual substrate, but selectively does not phosphorylate ACV, have also been described (13, 29, 42) . The existence of these TK-altered mutants suggests that an understanding of the structure of the enzymatic site for TK could lead to the development of more effective antiviral substrates or inhibitors of the enzyme. Unfortunately, only limited genetic analysis has been applied to understanding the structure of the active phosphorylating site of HSV TK. However, on the basis of the phenotypes of TK mutants with defined substrate specificities, a model was proposed in 1986 by Darby et al. (28) for the active center of the enzyme. In this model, three highly conserved regions act in concert. These regions include a nucleotide binding pocket, an ATP-binding site, and a thymidine-binding site. As more mutants are defined from clinical and laboratory isolates and more structure-function studies are performed, a clearer picture of the TK amino acids essential for catalytic activity should emerge (13, 14) . (50) . The academic interests in these studies took on very practical aspects with the isolation of clinical ACV-resistant mutants (24, 67, 115 (61, 91, 92) . ACV-and foscarnet-resistant mutants have been mapped primarily to regions I, II, and III and the A region, a relatively nonconserved sequence between IV and II. Marcy et al. (89) described mutants with changes in region I. These mutants were resistant to ACVTP and to phosphonoacetate, a pyrophosphate analog, indicating that this region is probably involved in substrate recognition. Indeed, many of the mutations also in regions II and III represent single amino acid changes, indicating that these regions may also be involved in substrate recognition. Since these regions and others (e.g., regions A and VII) are identified with drug resistance, it appears that interaction of the antiviral drugs with the DNA pol requires folding of the enzyme to provide important drug contact points at noncontiguous regions of the polypeptide.
The knowledge of the specific amino acid changes that alter drug susceptibilities of the HSV pol can also be used to evaluate the potential utility of novel inhibitors against ACV-resistant mutants. Matthews and his colleagues (92) have used this technique by generating previously described single-base-mutated HSV pols (57, 80) , resulting in single amino acid changes at sites within regions II and III. Following cloning and expression of the altered enzymes in yeasts, HSV pol enzymatic activities in the producer cell extracts were shown to display the same susceptibility or resistance phenotypes as those reported previously by Larder et al. (80) . Other mutant enzymes with a variety of base substitutions at the same sites were also generated and observed to retain enzymatic activities, indicating that these mutational sites were tolerant of extensive amino acid variation. However, these further amino acid substitutions did result in variations in the degree of resistance or hypersusceptibility to ACVTP and phosphonoacetate, respectively. When they were used to evaluate the novel cyclobutyl nucleoside analog 9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine triphosphate and the nucleotide analog 9-[2-(phosphonomethoxy)-ethyl]guanine diphosphate, all of the altered HSV pols, as well as the wild-type HSV pol, retained identical susceptibilities (92 (21) , and it was recognized that herpes zoster could be an early clinical sign of the development of AIDS (52).
Antiviral Drugs
VZV infections also respond clinically to the nucleoside analog antiviral agents ara-A and ACV and to the DNA pol inhibitor PFA. ara-A has shown clinical benefit in the treatment of VZV infections in both immune competent (3) and immunocompromised patients (125, 142) . However, as is the case for HSV infections, ACV has become the first-line treatment for recurrent infections caused by VZV and for both primary and recurrent disease in immunocompromised patients (4, 141) . Recently, ACV has shown clinical benefit in the treatment of chicken pox in otherwise healthy children (141) . PFA has shown efficacy in the treatment of ACV-resistant VZV infections in the AIDS population (117) . However, the intravenous mode of administration and renal toxicity may limit the clinical utility of this drug. It [22] ). However, in the absence of such laboratory documentation of resistant virus, physicians make therapeutic decisions on the basis of historical case reports. For this reason, we will briefly review several documented cases of drug resistance that illustrate key points in the chemotherapeutic management of chronic VZV disease and that highlight important features of the persisting virus.
One such case was that of a 27-year-old, HIV-seropositive patient with no previous history of varicella who presented with disseminated necrotic vesiculopustular lesions of 2 months duration (no pretherapy isolates recovered). The patient received intravenous ACV (length of treatment not stated), and VZV recovered from persistent lesions 1 year later appeared to be resistant in vitro (74) . In the severely immunosuppressed patient with AIDS, the inability to completely clear virus can result in a persistent infection in which it is difficult to clinically distinguish chronic varicella from chronic disseminated zoster. A second case documenting VZV drug resistance in a prolonged infection exemplifies the clinical circumstances in which drug resistance is likely to emerge and the genetic complexity of the resulting virus isolates. This case described continuous VZV infection in a 4-year-old child congenitally infected with HIV. The progressive cutaneous infection was clearly associated with ACV-resistant VZV (102) . The one isolate, recovered after 8 months of ACV therapy, was later shown phenotypically and genetically to consist of a complex mixture of TKdysfunctional virus, DNA pol-altered virus, virus containing both of these mutations, and wild-type virus (10) . The ACV-selected DNA pol mutation in this isolate conferred cross-resistance to PFA. This patient had responded to two initial courses of intravenous ACV therapy, but subsequent recurrences were poorly managed, with low, gradually escalating doses of oral therapy alternating with intravenous therapy. It is likely that inadequate drug dosing, in terms of quantity or duration, permitted the gradual evolution of this genetically heterogeneous isolate. This case illustrates a very important point: the role of suboptimal therapy in the selection of drug-resistant virus in the immunocompromised patient setting. These are the conditions used in the laboratory to select drug-resistant viruses.
The route of dosing may also be crucial in achieving optimal drug levels in plasma for the management of VZV disease. The bioavailability of ACV administered orally is more biologically variable than drug administered intravenously and may be limited in AIDS patients with gastrointestinal dysfunction due to other HIV-associated enteropathies (69). Jacobson et al. (69) described four HIV-infected patients in whom the gradual development of ACV-refractive disease could have resulted from such inadequate oral bioavailability of the drug. All four severely immunocompromised patients developed cutaneous VZV infections that initially responded to intravenous ACV induction therapy followed by oral ACV therapy. However, their disease subsequently recurred and evolved to yield ACV-resistant virus after chronic oral suppressive therapy of 1 to 5 months duration. These patients shed resistant virus from the atypical hyperkeratotic skin lesions that developed late in the chronic infection. Importantly, in only one of these four patients was initial therapy continued beyond the point of resolution of the VZV infection. This emphasizes the importance of timely, aggressive intervention to reduce the likelihood of the establishment of chronic persistent disease in AIDS patients. It also may be that monotherapy in the severely T-cell-depressed host cannot completely eliminate the burden of replicating virus, prompting consideration of combining or alternating drug therapeutic strategies for long-term suppression of persistent herpesvirus infections.
Although pretherapy isolates were not available for any of the cases described above, the initial infections were likely due to predominantly drug-susceptible VZV, since these patients responded to their early courses of therapy. Indeed, the isolation of ACV-resistant VZV in the non-HIV immunocompromised patient is a rare event (3) . The gradual progression of susceptible virus to resistance was carefully documented in one patient (65, 82 (117, 127) . The five patients in the Safrin study harbored 95 to 100% TK-(four patients) or TK-altered (one patient) VZV. Resistance to ACV had developed within 4-and 12-week intervals during ACV therapy in two patients. Only one of these patients (with TK-virus) failed to respond to PFA. In one of the responders, two serial VZV isolates recovered after 7 and 10 days of therapy had reduced susceptibility to PFA in vitro. Despite this, the patient healed with no recurrences. This same patient had again shed ACV-susceptible virus within 1 month after the ACV therapy was discontinued and before the PFA therapy was initiated. Two other patients again shed ACV-susceptible virus at the original lesion sites 7 and 14 days after discontinuing PFA treatment. One of these patients healed in response to intravenous ACV, while the other showed no response to 12 days of oral ACV therapy. These cases illustrate that the drug susceptibility phenotypes of VZV may rapidly change during or after antiviral therapy. The apparent instability of the TK-deficient phenotype provides a rationale for alternating therapies with PFA and the TK-dependent nucleoside analogs. It is clear from the above discussion that in the patient with AIDS the management of frequently recurring, persistent, or chronic VZV infections requires careful clinical and laboratory monitoring coupled with appropriate strategies of alternating or combining therapies, perhaps interspersed with intervals of therapy discontinuation. The relevance of drug-resistant virus to clinical outcome will await carefully controlled clinical studies. Likewise, the impact of the drug-resistant variants on the disease process in the individual patient and in the community remains to be determined. It is encouraging that the majority of the cases of chronic VZV infection involve locally progressive disease; visceral dissemination is rare. These features may point to the impaired pathogenesis of TK variants of VZV, like those of HSV. An examination of the nature of the TK gene mutations in these drug-resistant variants may yield information on the role of this enzyme in pathogenesis and in the herpesvirus phenomenon of latency and reactivation.
VZV TK Mutations Conferring Drug Resistance
The VZV-encoded TK is a 35-kDa polypeptide that possesses both thymidine and thymidylate kinase activities. While only the initial phosphorylation of ACV is carried out by this enzyme, both viral enzyme functions are required for the intracellular activation of bromovinyl deoxyuridine and the 5-substituted arabinofuranosyl analogs of deoxyuridine (bromovinyl uracil arabinoside and 5-propynyluracil arabinoside).
Laboratory strains of VZV, like those of HSV, have generally acquired drug resistance through mutations that resulted in the loss of functional TK production (8, 79, 96, 122) . Nucleotide deletions within the TK coding sequence have also been observed, and these generally cause frameshifts and premature termination of polypeptide synthesis, also resulting in the TK-negative phenotype (79) . Just as with HSV, VZV drug resistance has also occurred due to mutations that alter the affinities of the enzyme for nucleoside analog substrates, with concomitant changes in the affinity for the normal deoxypyrimidine substrates (126) . The distribution of laboratory TK mutant phenotypes is similar to that observed for HSV: the TK-deficient phenotype predominates.
The types of TK genetic lesions that arise in the clinic are similar to those described for HSV and laboratory-derived VZV drug-resistant mutants. However, there are not sufficient data to determine the relative frequency of the TKdeficient versus the TK-altered substrate phenotype. Correlation of the VZV TK gene sequences with enzyme function of 13 ACV-resistant strains purified from 10 different patients indicated that 4 of these strains were altered-substrate variants (114, 133) . One of these encoded an amino acid substitution in the ATP-binding site of the enzyme, while another encoded a substitution between the ATP-binding site and the nucleoside substrate-binding site. The remaining two altered-substrate mutants had single base changes in the regions encoding the nucleoside-binding sites. Two additional mutants with single amino acid substitutions in this region were severely crippled in enzyme function, and five other ACV-resistant strains contained nucleotide deletions of 1 to 4 bases in their TK genes, encoding nonfunctional, truncated polypeptides. In terms of the cross-resistance patterns of these ACV-resistant variants, three of the altered-substrate variants retained various degrees of susceptibility to bromovinyl uracil arabinoside. The in vitro susceptibility of TK-altered VZV strains to penciclovir paralleled that of ACV more closely.
Resistance Due to Altered VZV DNA Pol Mutations in the VZV DNA pol have been derived in the laboratory and recently have been recovered in the clinic. Similar to HSV, in VZV the mutations responsible for drug resistance consist of single base changes in the pol gene, which would result in single amino acid substitutions in conserved regions implicated in enzyme function ( Fig. 1)  (10, 53, 129 ). Although only six DNA pol variants of drugresistant VZV have been characterized, four of these showed amino acid substitutions that have also been implicated in the drug resistance phenotype of HSV. Laboratorygenerated resistance to ara-A mapped to conserved region II, and phosphonoacetate-selected resistance mapped to the most conserved region I of the polymerases, a region that appears to be relatively intolerant of mutation (89) . Of great interest is the observation that two independently derived ACV-resistant laboratory mutants of VZV possess the identical amino acid change (53) . This same asparagine-to-serine substitution had been identified previously in drug-resistant HSV DNA pol mutants (61, 80) . The cross-resistance patterns of these VZV DNA pol mutants were variable and, in most cases, similar to those of their HSV counterparts. These studies offer evidence for the functional importance of these conserved regions in enzyme function and for the close functional homology between the HSV and VZV enzymes as targets for antiviral inhibitors.
Two DNA pol variants of VZV have been reported in the clinical setting; both were recovered from patients with AIDS. The first variant was recovered in the heterogeneous isolate from the patient described by Pahwa and colleagues in 1989 (102) and which represented approximately 40% of the isolated virus at analyses (10) . The shown benefit in the prophylactic suppression of symptomatic disease in both renal allograft and allogeneic marrow transplant recipients (5, 94) , although these effects have not been consistent (40, 59) . The strategy of prophylactic intervention with a safe, but modest inhibitor may be facilitated by an oral prodrug of ACV, currently in clinical trials. ACV is not effective for the treatment of established clinical disease (reviewed by Whitley and Gnann [141] and Chou [18] ).
GCV has shown clear benefit as a preventive therapy, alone or in combination with immunoglobulin, in transplant recipients (48, 59, 123, 143) . GCV has clinical benefit in the treatment of retinitis, gastroenteritis, and liver disease, but the efficacy in pneumonitis has been questionable (93) . GCV is presently the drug of choice in the treatment of HCMV retinitis in AIDS patients and can effectively slow or halt the progressive retinal necrosis. However, the disease recurs rapidly when drug treatment is stopped (95, 106) . Maintenance therapy is therefore required, setting up conditions that favor the emergence of GCV-resistant virus (35) . The situation is complicated further by the presence of multiple strains of HCMV that can reactivate simultaneously or sequentially and that could potentially recombine (17, 38, 46) .
PFA is also an effective inhibitor of HCMV in vitro and recently has been approved for the treatment of CMV retinitis in immunocompromised patients (19, 68, 73, 103 ). PFA appears to be comparable to GCV in controlling retinitis when given as either induction or maintenance therapy (reviewed by Balfour et al. [6] ). As with GCV suppression, PFA maintenance therapy must be continuous in patients with advanced AIDS (70, 72) . The toxicity profiles and the modes of action are different for these two antiviral agents, which allows strategic flexibility in accommodating the toxicities of adjunct therapies and in dealing with drug-resistant virus infections (39, 71, 78) . There is one case report of an HIV-positive patient whose HCMV encephalitis was successfully resolved by the addition of PFA to a regimen of GCV, which was ineffective as monotherapy (109) .
It has been difficult to define HCMV drug resistance in vitro, since there is no standardized assay. In published studies, HCMV shows a broad range of susceptibility to GCV, with 50% inhibitory concentration (IC50) values ranging from 0.5 to 8 ,uM (23, 49, 111, 124, 135) . Data have been derived by different assays in various fibroblast cells, and pretherapy isolates are not always available for direct comparisons. Moreover, the isolates may consist of complex mixtures of phenotypes and strains with changing drug susceptibilities. As published for the characterization of both HSV and VZV clinical isolates, the drug IC90 to IC95 values may provide the most sensitive indicators of the presence of drug-resistant virus. Importantly, the GCV or PFA susceptibilities measured in vitro for resistant viruses may be only 5-to 10-fold higher than those measured for susceptible strains. On the basis of cumulative GCV susceptibility studies performed to date, Drew et al. have proposed 12 ,uM as an approximate cutoff value for the IC50 value of drugsusceptible strains (37) . However, because of the variability in assay systems, it is prudent to compare single isolates with several GCV-susceptible reference strains tested simultaneously (107). It is important to review the evidence for GCV resistance in the clinic with these complexities in mind.
Before the Hirsch and Schooley editorial, there was little evidence that drug resistance of HCMV correlated with poor clinical outcome in the transplant setting (23, 124) . However, as pointed out by Hirsch and Schooley (64) , in the more immunocompromised patient setting, the evidence for GCV resistance has clearly been demonstrated and correlated with the clinical outcome. The report by Erice et al. in 1989 (46) , which prompted editorial comment, documented resistance in blood isolates recovered from three severely immunocompromised patients (one with chronic lymphocytic leukemia and two with AIDS). These case reports illustrated the familiar scenario in which early courses of therapy produced some transient clinical benefit but viremia never totally cleared, and the infections relentlessly progressed. Resistant isolates were subsequently recovered after 80 to 130 days of GCV therapy. The GCV IC50 values for these resistant isolates were only three-to sevenfold higher than those isolates obtained early in the course of therapy or the reference strain, while the IC90 values showed a more convincing elevation of 17-to 43-fold compared with the controls. One of these patients shed two different HCMV strains, on the basis of the DNA restriction enzyme profile, and both were GCV resistant (128). All three patients described in this report harbored a heavy burden of replicating virus, as evidenced by the recovery of multiple isolates from many sites throughout the protracted clinical course. VOL. 7, 1994 on The recovery of virus with in vitro resistance to GCV was clearly correlated with clinical failure of the drug and disease progression.
Since this initial report documenting GCV-resistant HCMV, others have also reported the recovery of GCVresistant virus from AIDS patients following prolonged therapy (37, 55a) . There have been two reports of AIDS patients who developed HCMV polyradiculomyelitis while receiving GCV for retinitis (30, 41) . In vitro, GCV resistance was documented for an isolate recovered from the cerebral spinal fluid of one of these two patients after several months of GCV treatment (41) . The GCV IC50 value of this isolate was 18.5 ,uM; there was no mention of earlier isolates for comparison.
The incidence of GCV resistance in AIDS patients who receive GCV maintenance therapy for HCMV retinitis has been estimated at 7.6% by Drew et al. (37) . In a prospective study of 72 patients, no resistant strains were identified in 31 patients before GCV therapy or in 7 culture-positive patients treated for less than 3 months. However, 5 of 13 patients who shed virus after more than 3 months of therapy showed evidence of GCV resistance in their isolates (IC50, > These isolates could consist of evolving mixtures of wildtype and drug-resistant viruses. IC50 values for the susceptible isolates ranged from 0.5 to 3 ,uM in a plaque reduction assay. However, the progression of HCMV retinitis could not be clearly correlated with the presence of resistant virus in urinary HCMV isolates. The overall response rate was 80% in this study of 72 patients after 1 to 2 months of therapy, and it remained at 80% for survivors on therapy after 7 months. The impact of drug-resistant virus on patient outcome may reflect the management of underlying HIV disease in this patient population. Clearly, the pathogenesis of HCMV is not well understood, and the relationship of viruria and even viremia to virus load and disease in various organs remains to be determined.
GCV Resistance Due to Altered UL97-Encoded
Phosphotransferase The basis for GCV resistance in 10 HCMV strains recovered from eight immunocompromised patients who failed long-term GCV therapy was the inability of these viruses to induce GCV phosphorylation in virus-infected cells (128) . These strains included five strains that were plaque purified from resistant isolates recovered from the three patients described by Erice and colleagues (46) and five resistant isolates reported in the prevalence study by Drew et al. (37) . By contrast, the available pretherapy GCV-susceptible virus isolates were competent for the induction of GCV anabolism in cells. The DNA pols of these purified strains did not appear to play a role in this GCV resistance on the basis of the overall drug susceptibility profile to other DNA pol inhibitors [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and PFA]. The DNA pol functions were comparable for the enzymes induced by one clinical pair of GCV-susceptible and GCV-resistant strains.
The phenotype of these GCV-resistant isolates is similar to that of TK-deficient, ACV-resistant HSV or VZV. However, genetic and biochemical studies have shown that HCMV lacks a TK analogous to the HSV or VZV TK. Yet the selective anabolism of GCV in HCMV-infected cells is clearly required for the antiviral action of the drug (9, 11) . There is a direct correlation between the in vitro suscepti- bility of laboratory and clinical HCMV strains to GCV and the intracellular levels of GCV nucleotides (Fig. 2) . The mechanism of selective induction of GCV phosphates by HCMV remained a puzzle until the availability of a GCVresistant laboratory mutant, 759rD100, with the phosphorylation-deficient phenotype (9) . This laboratory mutant was used to map the resistance phenotype to the HCMV UL97 open reading frame of the HCMV genome (132) . The 78-kDa protein encoded by UL97 shares homology with several protein kinases, guanylyl cyclase, and bacterial aminoglycoside phosphotransferases (16) . The GCV resistance mutation in this laboratory-derived strain consisted of a 12-bp deletion that would result in a 4-amino-acid deletion in a region of the polypeptide conserved among protein kinases and which in cyclic AMP-dependent protein kinase plays a role in substrate recognition. Supporting evidence for the direct phosphorylation of GCV by the UL97 gene product was provided by Littler and colleagues (83) , who expressed active GCV phosphorylating activity of the UL97 gene in a bacterial system. Therefore, the apparently predominant GCV resistance mechanism observed in the clinic is associated with the GCV anabolism-deficient phenotype, which apparently results from mutations in the UL97 gene. (25, 98) . The UL13 polypeptide immunoprecipitated from virus-infected cells was shown to have protein kinase activity (25) . In addition, the homolog of VZV recently has been reported to phosphorylate the assembly protein of VZV (97) . However, the full function of these protein kinase homologs in virus replication and infection remains to be determined. Drug Resistance Due to Altered HCMV DNA Pol The HCMV DNA pol is the ultimate target for a number of nucleoside analog triphosphates and for PFA (87) . In addition to the major mechanism of UL97 mutation, GCV resistance in HCMV can also result from DNA pol mutations (85, 130) . One laboratory-derived, GCV-resistant mutant of AD169 possessed both a UL97 mutation (132) (134) . Since this GCV-resistant virus was competent for GCV phosphorylation, it is likely that a DNA pol alteration was solely responsible for the drug resistance phenotype.
PFA resistance of HCMV has been described in the laboratory setting (27, 131) and more recently in the clinic (78) . The mutations associated with this resistance phenotype were not identified in these cases, nor were the confirmatory genetic experiments performed. However, on the basis of the experience with HSV and VZV, HCMV should be expected to develop resistance to PFA in the clinical setting, with direct PFA selection pressure, or potentially under GCV, ACV, or HPMPC therapy.
EBV
As with other herpesviruses, EBV can cause productive viral infections leading to cell lysis and persistent latent infection. Unlike the other human herpesviruses described above, EBV is associated with a wide array of diseases that reflect pathology resulting either from direct cytolysis enhanced by the host immune response to viral antigens or from the capacity of the latent virus to immortalize cells, resulting in neoplasia. Perhaps because of this clinically diverse pathology, which is still undergoing characterization, antiviral therapy has not had a major role in the treatment of EBV-associated diseases. More detailed discussions of the virology and diseases associated with EBV are presented superbly by Pagano in a recent series of articles (99) (100) (101) . For the purposes of this review, we will summarize these diseases and the therapeutic approaches. Only meager information is available concerning drug resistance, reflecting the difficulties in readily screening for resistance with the available in vitro systems (101 (101) . EBV is also the cause of the great majority of cases of infectious mononucleosis, the symptoms of which result from cytolytic virus replication in the oropharynx, immunopathology of other organs, and a proliferation of cytolytic T cells in response to antigens shed from virus-infected cells (101) . Although ACV can be effective in halting the replication of EBV in cell culture and has been used for intramuscular treatment, the results have not been encouraging (137) , and problems of drug resistance have not emerged. In nasopharyngeal carcinoma, EBV DNA is detected in episomal form and the virus does not replicate in the preneoplastic lesions or the carcinoma cells (112) . Nasopharyngeal carcinoma is a neoplasm that has a very high prevalence in Southern China. In the early stages of disease, immunoglobulin A antibodies to EBV replicative antigens appear, suggesting that at this stage of disease cytolytic virus replication may be important and that conventional antiviral agents might be effective (101) . To date, antiviral drugs have not been used against nasopharyngeal carcinoma, and effective means to block the expression of transforming genes of episomal EBV are not at hand. The disease pattern described for nasopharyngeal carcinoma seems similar to that now seen in a rising incidence of B-cell tumors in immunocompromised hosts, especially AIDS patients (86) . The B-cell lymphomas often carry episomal EBV DNA and are probably the result of EBV transformation. However, there is also viral reactivation resulting in productive infection, leaving open the opportunity for antiviral chemotherapy (77, 101) .
The most recent disease associated with EBV is hairy leukoplakia, a disease recognized in AIDS patients and characterized by tongue lesions composed of proliferating and productively infected epithelial cells (120) . Hairy leukoplakia responds to ACV treatment, as might be expected since the disease is not associated with latently EBVinfected proliferating cells (62) . However, the disease recurs, perhaps as a result of development of resistant virus. Hairy leukoplakia lesions are infected with multiple strains of EBV (138) , with the potential for generating recombinants with altered drug susceptibilities. ACV-resistant strains of EBV have not yet been isolated and characterized, but hairy leukoplakia would appear to be the best candidate EBVassociated disease for which antiviral chemotherapy could be effectively applied and for which drug-resistant EBV variants would arise. will be accompanied by the emergence of new drug-resistant virus strains. As Hirsch and Schooley appropriately indicated, "the public health implications of emerging resistance to antiviral agents are considerable" (64) . Will we see the spread of drug-resistant strains from patient to patient and from immunocompromised patients to immunocompetent, healthy individuals? Will virus strains emerge that have enhanced virulence? Will the pipeline of new drug development be primed to produce novel therapeutically effective agents against the resistant virus strains? And will the judicious use of drugs in combination and at appropriate intervals effectively keep the resistant strains suppressed and not provide the selective pressure favorable for drugresistant virus replication? The bad news is that the problem of resistance can be expected to grow, but the good news is that clinicians and virologists are increasingly aware and challenged toward monitoring for resistance, characterizing the mechanisms of resistance, and responding with the most appropriate therapeutic modalities available.
